Your institution may have access to this item. Find your institution then sign in to continue.
Title
Finances.
Abstract
Reports on Elusys Therapeutics Inc.'s receipt of an additional 5.4 million dollars from the National Institute of Allergy and Infectious Diseases for continued research of Anthim, a monoclonal antibody being developed for the prevention and treatment of anthrax infection.